[1] Bower JH, Maraganore DM, McDonnell SK, et al.Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology.1999;52: 1214-1220.
[2] de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology.1995;45: 2143-46.
[3] Doty RL, Bromley SM, Stern MB.Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurodegeneration.1995;4: 93-97.
[4] Iranzo A, Santamaría J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology.2005;65: 247-252.
[5] Andrew JL, John H,Tamas R. Parkinson’s disease. Lancet. 2009;373: 2055-2066.
[6] Paísan-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron.2004;44: 595-600.
[7] Healy DG, Falchi M, O-Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol.2008;7: 583-590.
[8] Ozansoy M, Ba?ak AN.The Central Theme of Parkinson’s Disease: α-Synuclein.Mol Neurobiol.2013;47:460-465.
[9] Tanner CM.Is the cause of Parkinson’s disease environmental or hereditary? Evidence from twin studies. Adv Neurol.2003; 91:133-142.
[10] Taylor KS, Counsell CE, Gordon JC, et al. Screening for undiagnosed parkinsonism among older people in general practice. Age Ageing.2005;34: 501-504.
[11] Dick FD, De PG, Ahmadi A, et al.Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med.2007; 64: 666-672.
[12] [Clark IE,Dodson MW,Jiang C,et al.Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature.2006; 441: 1162-1166.
[13] Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature.2006; 441: 1157-1161.
[14] Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord.2006; 21: 1806-1823.
[15] Allam, MF,Campbell MJ,Hofman A,et al.Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord, 2004; 19: 614-621.
[16] Hernán MA,Zhang SM,Rueda-deCastro AM,et al. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies. Ann Neurol.2001; 50: 780-786.
[17] Ascherio A, Weisskopf MG, O’Reilly EJ.Co?ee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying e? ects of estrogen. Am J Epidemiol.2004; 160: 977-984..
[18] Ascherio A, Chen H, Schwarzschild MA, et al. Ca?eine, postmenopausal estrogen, and risk of Parkinson‘s disease. Neurology.2003; 60: 790-795.
[19] Evans AH, Lawrence AD,Potts J.Relationship between impulsive sensation seeking traits, smoking, alcohol and ca? eine intake, and Parkinson’s disease. J Neurol Neurosurg Psychiatry.2006; 77: 317-321.
[20] Sundberg, Bogetofte, Lawson et al.Improved Cell Therapy Protocols for Parkinson’s Disease Based on Differentiation Ef?ciency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons. stem cells. 2013;31:1548-1562.
[21] Yan Z, Maosheng S, Hongjun L,et al.Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and stem cell therapy. Cytotherapy. 2013; 15(4):467-480.
[22] Katzenschlager R, Head J, Schraq A, et al.Fourteen-year ? nal report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71: 474-480.
[23] Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med.2004;351: 2498-508.
[24] Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord.2008; 23: 837-844.
[25] Kim JH, Auerbach JM, Rodríguez-Gómez JA, et al.Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature. 2002; 418: 50-56.
[26] Ben-Hur T, Idelson M, Khaner H, et al.Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells.2004; 22: 1246-1255.
[27] Kurowska Z, Englund E, Widner H, et al. Signs of Degeneration in 12–22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson’s Disease. J Parkinsons Dis. 2011;1(1):83-92.
[28] Pawitan JA. Prospect of cell therapy for Parkinson’s disease. Anat Cell Biol. 2011;44:256-264.
[29] Anders B, Kordower JH. Cell Therapy for Parkinson’s Disease: What Next?. Movement Disorders.2013;28(1):110-115.
[30] Duke CM, Taylor HS.Stem cells and the reproductive system: Historical perspective and future directions. Maturitas. 2013; 6036(10):1-6.
[31] Seung UK, Hong JL, Yun BK. Neural stem cell-based treatment for neurodegenerative diseases. Neuropathology. 2013;33: 491–504.
[32] Sun J, Gao Y, Yang L, et al. Neural-tube-derived neuroepithelial stem cells: a new transplant resource for Parkinson’s disease. Neuroreport. 2007;18(6):543-547.
[33] 王家增.GFP转基因鼠胚胎神经上皮干细胞的体外培养[J]. 山东大学学报:医学版, 2009,47(9):49-53.
[34] 郑敏,王亚平,裴雪涛,等.神经干细胞移植对帕金森病模型大鼠的治疗作用[J].基础医学与临床,2007,27(8):841-845.
[35] Serra PA, Esposito G, Enrico P, et al. Manganese increases L-DOPA autooxidation in the striatum of the freelymoving rat: potential implications to L-DOPA long-term therapy of Parkinson’s disease.Br J Pharmacol.2000; 130(4): 937-945.
[36] 王家增. 携带绿色荧光蛋白基因的神经上皮干细胞移植治疗帕金森病[J].中国组织工程研究,2012;16(6):1080-1084.
[37] Jinhao S, Qing G, Katherine M, et al.Dopaminergic differentiation of grafted GFP transgenic neuroepithelial stem cells in the brain of a rat model of parkinson’s disease. Neurosci Lett. 2007;420(5): 23-28.
[38] 王普清,孙圣刚,张允健,等黑质内注射脂多糖对多巴胺能神经元和小胶质细胞活性的影响[J].中国康复,2008;23(6):380-382.
[39] Caplan AI.Why are MSCs therapeutic? New data: new insight. J Pathol.2009;217(2): 318-324.
[40] Hegarty SV, Sullivan AM, O'Keeffe GW. Midbrain dopaminergic neurons: A review of the molecular circuitry that regulates their development. Dev Biol. 2013;379(2):123-38.
[41] Shan X,Chi L,Bishop M,et al.Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells.2006;24(5) : 1280-1287.
[42] van den Berge SA, van Strien ME, Hol EM. Resident adult neural stem cells in Parkinson’s disease-The brain’s own repair system?.Eur J Pharmacol.2013;4:058-069.
[43] Nishino H, Hida H, Takei N, et al. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp Neurol.2000;164(1):209-214.
[44] Hurelbrink CB, Armstrong RJ, Dunnett SB, et al. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci. 2002;15(7):1255-1266.
[45] Tamaki S, Eckert K, He D, et al. Engraftment for sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res.2002;69(6):976-986.
[46] Fei L, Jiang CC, Feng LY, et al.Transplantation of primary cultured embryonic mesencephalic neural precursor cells for treating Parkinsonian rats.Neural Regen Res.2006;1(1):6-9. |